biostudies-literatureUnknown18(12)Becker S<h4>Background</h4>Allergen Immunotherapy (AIT) is an effective treatment for patients with pollen, house dust mite, or venom allergy, but treatment adherence can be challenging. Patient preferences play a crucial role in acceptance and adherence to AIT, but little is known about these preferences. This study aimed to understand patient preferences for AIT and how these preferences influence treatment acceptance.<h4>Methods</h4>A conjoint analysis was conducted among 750 participants from 7 European countries who were allergic to pollen (n = 700) or Hymenoptera venom (n = 50) and had not previously received AIT. Participants were asked to choose between hypothetical AIT products with different attributes, including product type, initial up-dosing posology, potential future risks, and side The World Allergy Organization journal101154https://www.ebi.ac.uk/biostudies/studies/S-EPMC12765409biostudies-literaturePatient preference in allergen immunotherapy - Understanding the patient's view.PMC12765409Klimek LHofer GBirkholz KJensen-Jarolim ERaab JOllert MKramer MFSchmid-Grendelmeier PBecker SFuchs OFeindor MAbro RFassio FBlank SGraessel AFernandez de Alba IGonzalez-de-Olano DValentine NHernandez DfalsePatient preference in allergen immunotherapy - Understanding the patient's view.<h4>Background</h4>Allergen Immunotherapy (AIT) is an effective treatment for patients with pollen, house dust mite, or venom allergy, but treatment adherence can be challenging. Patient preferences play a crucial role in acceptance and adherence to AIT, but little is known about these preferences. This study aimed to understand patient preferences for AIT and how these preferences influence treatment acceptance.<h4>Methods</h4>A conjoint analysis was conducted among 750 participants from 7 European countries who were allergic to pollen (n = 700) or Hymenoptera venom (n = 50) and had not previously received AIT. Participants were asked to choose between hypothetical AIT products with different attributes, including product type, initial up-dosing posology, potential future risks, and side 2025-01-01T00:00:00Z2025 Dec2026-06-10T04:58:50.462Z2026-06-10T03:07:39.464ZS-EPMC127654094149242310.1016/j.waojou.2025.101154